It is clear within the global health science industry that analytical biosafety testing and advances in developing scientific technologies will play an important role in drug development’s response to the next pandemic.
The emergence of SARS-CoV-2 in December 2019, and the subsequent declaration of a global pandemic by the World Health Organisation in March 2020, had an unprecedented impact on drug development. Many sponsors – from emerging biotechs to big pharma - found themselves grappling with the need to assure supply to patients enrolled in existing studies while transforming R&D pipelines to accommodate the urgent need for safe and effective Covid-19 vaccines and treatments.
